Vnitr Lek 2025, 71(6):365-371 | DOI: 10.36290/vnl.2025.069

Current options for pharmacotherapy of obesity

Ľubica Cibičková
Diabetologické centrum, 3. interní klinika, Fakultní nemocnice Olomouc
Interní a diabetologická ambulance AIDIN VK, s. r. o., Hranice

Antiobesity medication are one of the options to promote weight loss, especially when dietary measures and physical activity do not bring the expected results. However, their use should always be part of a comprehensive approach to obesity treatment that includes a healthy diet, exercise and psychological support. In recent years, we have seen an increase in the availability of pharmacotherapy for obesity, so that we can individualise treatment and try to 'tailor it to the patient'. The popular drug phentermine (Adipex), which acts on the central nervous system and helps to suppress appetite, has been withdrawn from the market relatively recently. Of the older drugs, orlistat (Xenical) remains on the market, and more recently naltrexone/bupropion (Mysimba), liraglutide (Saxenda), tirzepatide (Mounjaro) and semaglutide (Wegovy) are used to treat obesity.

Keywords: obesity, antiobesitic drugs, semaglutide, naltrexone/bupropione, tirzepatide, GLP-1 agonists.

Accepted: September 21, 2025; Published: October 2, 2025  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Cibičková Ľ. Current options for pharmacotherapy of obesity. Vnitr Lek. 2025;71(6):365-371. doi: 10.36290/vnl.2025.069.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Karnosova P. Současné možnosti a praktické aspekty terapie antiobezitiky v ordinaci praktického lékaře. Med. Praxi. 2025;25(1):316-321.
    2. Torgerson JS, Hauptman J, Boldrin MN, et al. XENical in the Prevention of Diabetes in Obese Subjects (XENDOS) Study: A randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 1 January 2004;27(1):155-161. Go to original source...
    3. Brychta T, Brychtová S. Orlistat v terapii obezity. Med. Pro Praxi 2010; 7(3): 145-148.
    4. Zafarova Z. Med. Praxi. 2024;21(3):170-176. Go to original source...
    5. Glider K, Dalto, M, Halseth A, et al. PP5.13 Food craving and weight loss: An integrated analysis of the effects of prolonged release naltrexone/bupropion on the cravings and mood subscales of the Control of Eating Questionnaire. Obesity Facts. 2016;9(suppl 1):80-80.
    6. SPC Mysimba. www.sukl.cz.
    7. Walsh B, Plodkowski RA, Shan K, et al. T8:PO.108 Early achievement of significant weight loss with prolonged release naltrexone/bupropion is associated with additional weight loss at one year - an integrated analysis of four phase 3 trials. Obesity Facts. 2015;8(suppl 1):240-240.
    8. Arturi F, Succurro E, Micelli S, et al. Liraglutide improves cardiac function in patients with type 2 diabetes and chronic heart failure. Endocrine. 2017 Sep;57(3):464-73. Go to original source...
    9. Pi-Sunyer X, Astrup A, Fujioka K, et al.; SCALE Obesity and Prediabetes NN8022-1839 Study Group. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. N Engl J Med. 2015 Jul 2;373(1):11-22. Go to original source...
    10. le Roux CW, Astrup A, Fujioka K, et al.; SCALE Obesity Prediabetes NN8022-1839 Study Group. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial. Lancet. 2017;389:1399-409. Go to original source...
    11. Fried M, Svačina Š. Moderní trendy v léčbě obezity a diabetu. Mlečice (CZ): Axonite CZ; 2018. 136 p. Czech.
    12. Saxenda 6 mg/ml inj sol pep 3 × 3 ml. Souhrn údajů o přípravku. (www.sukl.cz).
    13. Račická E. Současné možnosti léčby diabetes mellitus 2. typu pomocí agonistů GLP-1. Farmakoter Revue 2019;4(1):74-82.
    14. Haluzík R. Semaglutid. Remedia 2019;26:25-31. Go to original source...
    15. Rasmussen MF. The development of oral semaglutide, an oral GLP-1 analog, for the treatment of type 2 diabetes. Diab etol Int 2020 Jan 4;11(2):76-86. Go to original source...
    16. Račická E. Semaglutid - první perorální agonista receptorů GLP-1 a jeho postavení v léčbě diabetu. Farmakoter revue 2022;7(1):51-56.
    17. Sattar N, Lee MMY, Kristensen SL, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials. Lancet Diabetes Endocrinol. 2021;9(10):653-662. Go to original source...
    18. Husain M, Birkenfeld AL, Donsmark M, et al. Oral semaglutide and cardiovascular outcomes in patients with Type 2 diabetes. N Engl J Med. 2019;381:841-851. Go to original source... Go to PubMed...
    19. Strain DW, Frenkel O, James MA, et al. Effects of semaglutide on stroke subtypes in type 2 diabetes: post hoc analysis of the randomized SUSTAIN 6 and PIONEER 6. Stroke. 2022;53:2749-2757. Go to original source... Go to PubMed...
    20. Prosecký R, Vítovec J. Tirzepatid - nová naděje v léčbě obezity a nové antidiabetikum. Klin Farmakol Farm 2023;37(2):68-71. Go to original source...
    21. Kahn SE, Deanfield JE, Jeppesen OK, et al.; SELECT Trial Investigators. Effect of Semaglutide on Regression and Progression of Glycemia in People With Overweight or Obesity but Without Diabetes in the SELECT Trial. Diabetes Care. 2024 Aug 1;47(8):1350-1359. Go to original source... Go to PubMed...

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.